CHANGE TO VECTOR FULL

Uniting ForgeвЂ™s integrated platforms and cGMP gene therapy manufacturing capabilities with our in-depth knowledge in high dose gene therapy development and manufacturing will introduce an additional method to produce AAV gene therapy at Solid, and help to accelerate human proof of concept for SGT-003.вЂќ вЂњAs we continue to develop our pipeline, it is important that we have partners who will enhance our expertise. вЂњWe are excited to partner with Forge, a company who shares our high standards for product purity, potency and reproducibility, to further our ability to bring meaningful therapies to patients with Duchenne,вЂќ said Joel Schneider, Ph.D., Chief Operating Officer of Solid Biosciences.

All development and cGMP manufacturing activities will occur at The Hearth, ForgeвЂ™s 175,000 ft 2 gene therapy cGMP production facility in Columbus, Ohio. The program will employ ForgeвЂ™s Blaze Vectorв„ў production platform, and ForgeвЂ™s proprietary HEK293 suspension Ignition Cellsв„ў and pEMBRв„ў advenovirus helper plasmid, to support SolidвЂ™s clinical development.

CHANGE TO VECTOR FULL

View the full release here: ДЇorge will provide an adeno-associated viral (AAV) vector process, scale-up engineering and cGMP manufacturing services for SGT-003. SGT-003 is a preclinical candidate that combines a next-generation and rationally designed capsid with SolidвЂ™s proprietary nNOS-containing microdystrophin and has demonstrated enhanced muscle tropism and microdystrophin expression compared to AAV9 in vivo.

(Solid, Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), and Forge Biologics, a cell and gene therapy-focused contract development and manufacturing organization (CDMO), announced a partnership to advance the development and manufacturing of SGT-003, SolidвЂ™s next generation gene therapy program for Duchenne.

Change to vector